Obstructive sleep apnea syndrome and cardiovascular diseases: from diagnosis to personalized therapy (part 1)
https://doi.org/10.18705/2782-3806-2022-2-2-46-53
Abstract
The review discusses the relevance of the problem of obstructive sleep apnea syndrome in real clinical practice, features of diagnostics and a personalized approach to therapy considering various comorbid conditions, a review of the results of major clinical studies and recommendations. Literature search and selection of clinical studies was carried out for the period from 2000 to 2020 on the websites of the European and Russian Societies of Cardiology, as well as databases PubMed, eLibrary, Google Scholar.
About the Authors
V. A. Ionin
Pavlov St-Petersburg State Medical University
Russian Federation
Russian Federation
Valery A. Ionin, PhD, Associate Professor, Senior Researcher Federal State Budgetary Educational Institution of Higher Education "First St. Petersburg State Medical University named after Academician I. P. Pavlov"
Department of faculty therapy with a course of endocrinology,
cardiology with a clinic named after acad. G. F. Lang
phone: +79213727684
Saint-Petersburg
V. A. Pavlova
Pavlov St-Petersburg State Medical University
Russian Federation
Russian Federation
Victoria A. Pavlova, Clinical Resident
Federal State Budgetary Educational Institution of Higher Education "First St. Petersburg State Medical University named after Academician I. P. Pavlov"
Department of faculty therapy with a course of endocrinology, cardiology with a clinic named after acad. G. F. Lang
Saint-Petersburg
E. I. Baranova
Pavlov St-Petersburg State Medical University; Almazov National Medical Research Centre
Russian Federation
Russian Federation
Elena I. Baranova, MD, Professor, , Director, Head
Federal State Budgetary Educational Institution of Higher Education "First St. Petersburg State Medical University named after Academician I. P. Pavlov"; Federal State Budgetary Institution "National Medical Research Center named after V. A. Almazov"
Department of faculty therapy with a course of endocrinology, cardiology with a clinic named after acad. G. F. Lang
Institute of Endocrinology
NILE metabolic syndrome
Saint-Petersburg
References
1. Ge L., Guyatt G., Tian J., Pan B., Chang Y., Chen Y., et al. Insomnia and risk of mortality from all-cause, cardiovascular disease, and cancer: Systematic review and meta-analysis of prospective cohort studies. Sleep Medicine Reviews 2019; 48. https://doi.org/10.1016/J.SMRV.2019.101215.
2. Kerkhof G. A. Epidemiology of sleep and sleep disorders in The Netherlands. Sleep Medicine 2017; 30: 229–39. https://doi.org/10.1016/J.SLEEP.2016.09.015.
3. Qaseem A., Holty J. E. C., Owens D. K., Dallas P., Starkey M., Shekelle P. Management of obstructive sleep apnea in adults: A clinical practice guideline from the American College of Physicians. Annals of Internal Medicine 2013; 159: 471–83. https://doi.org/10.7326/0003-4819-159-7-201310010-00704.
4. Myers K. A., Mrkobrada M., Simel D. L. Does this patient have obstructive sleep apnea?: The Rational Clinical Examination systematic review. JAMA 2013; 310: 731–41. https://doi.org/10.1001/JAMA.2013.276185.
5. Kasai T., Floras J. S., Bradley T. D. Sleep apnea and cardiovascular disease: a bidirectional relationship. Circulation 2012; 126: 1495–510. https://doi.org/10.1161/CIRCULATIONAHA.111.070813.
6. Gorbunova M. V., Babak S. L., Malyavin A. G. Rational antihypertensive therapy in patients with obstructive sleep apnea. The Russian Archives of Internal Medicine 2019; 9: 85–92. [Горбунова М. В. Рациональная антигипертензивная терапия пациентов с обструктивным апноэ сна / М. В. Горбунова, С. Л. Бабак, А. Г. Малявин. – Архивъ Внутренней Медицины. – 2019. – 9: 85–92. https://cyberleninka.ru/article/n/ratsionalnaya-antigipertenzivnaya-terapiya-patsientov-s-obstruktivnym-apnoe-sna?]
7. Duarte R. L. M., Magalhães-da-Silveira F. J., Gozal D. Predictive Factors for Obstructive Sleep Apnea Diagnosis in Bariatric Surgery Candidates with or Without Chronic Insomnia Complaints. Obesity Surgery 2022; 32: 33–41. https://doi.org/10.1007/S11695-021-05748-5.
8. Chizhova O. Yu. The role of obstructive sleep apnea in the development of metabolic syndrome and obesity. Herald of North-Western State Medical University named after I. I. Mechnikov. 2019; 11 (2): 49–52. [Чижова О. Ю. Значение обструктивных апноэ сна в развитии метаболического синдрома и ожирения / О. Ю. Чижова // Вестник Северо-Западного государственного медицинского университета им. И. И. Мечникова. – 2019. – 11: 49–52. https://cyberleninka.ru/article/n/znachenie-obstruktivnyh-apnoe-sna-v-razvitii-metabolicheskogo-sindroma-i-ozhireniya?]
9. Arnardottir E. S., Maislin G., Schwab R. J., Staley B., Benediktsdottir B., Olafsson I., et al. The interaction of obstructive sleep apnea and obesity on the inflammatory markers C-reactive protein and interleukin-6: the Icelandic Sleep Apnea Cohort. Sleep 2012; 35: 921–32. https://doi.org/10.5665/SLEEP.1952.
10. Punjabi N. M. Do sleep disorders and associated treatments impact glucose metabolism? Drugs 2009; 69 Suppl 2:13–27. https://doi.org/10.2165/11531150-000000000-00000.
11. Meslier N. [Sleep apnea syndromes, metabolic syndrome and insulin resistance]. Revue Des Maladies Respiratoires 2006; 23 Spec No 2. https://doi.org/10.1016/S0761-8425(06)72487-1.
12. Barceló A., Barbé F., de La Peña M., Martinez P., Soriano J. B., Piérola J., et al. Insulin resistance and daytime sleepiness in patients with sleep apnoea. Thorax 2008; 63: 946–50. https://doi.org/10.1136/THX.2007.093740.
13. McNicholas W. T., Bonsignore M. R. Sleep apnoea as an independent risk factor for cardiovascular disease: current evidence, basic mechanisms and research priorities. The European Respiratory Journal 2007; 29: 156–78. https://doi.org/10.1183/09031936.00027406.
14. Peppard P. E., Young T., Palta M., Dempsey J., Skatrud J. Longitudinal study of moderate weight change and sleep-disordered breathing. JAMA 2000; 284: 3015–21. https://doi.org/10.1001/JAMA.284.23.3015.
15. Hoyos C. M., Killick R., Keenan D. M., Baxter R. C., Veldhuis J. D., Liu P. Y. Continuous positive airway pressure increases pulsatile growth hormone secretion and circulating insulin-like growth factor-1 in a time-dependent manner in men with obstructive sleep apnea: a randomized sham-controlled study. Sleep 2014; 37: 733–41. https://doi.org/10.5665/SLEEP.3580.
16. Deflandre E., Gerdom A., Lamarque C., Bertrand B. Understanding Pathophysiological Concepts Leading to Obstructive Apnea. Obesity Surgery 2018; 28: 2560–71. https://doi.org/10.1007/S11695-018-3325-6.
17. Blackman A., Foster G. D., Zammit G., Rosenberg R., Aronne L., Wadden T., et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. International Journal of Obesity (2005) 2016; 40: 1310–9. https://doi.org/10.1038/IJO.2016.52.
18. Strueva N. V., Melnichenko G. A., Poluektov M. G., Savelyeva L. V. The efficiency of obesity treatment in patients with insomnia and obstructive sleep apnea syndrome. Obesity and metabolism. 2016; 13 (2): 26–32. [Струева Н. В. Эффективность лечения ожирения у больных с инсомнией и синдромом обструктивного апноэ сна / Н. В. Струева [и др.] // Ожирение и Метаболизм. – 2015. – 13: 25–32. https://cyberleninka.ru/article/n/effektivnost-lecheniya-ozhireniya-u-bolnyh-s-insomniey-i-sindromom-obstruktivnogo-apnoe-sna?]
19. Burchakov D. I., Mayorov A. Yu. CPAP-THERAPY DECREASES GLYCATED HEMOGLOBIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND SLEEP APNOEA. Medical Council 2017:132–5. https://doi.org/10.21518/2079-701X-2017-10-132-135.
20. Hassaballa H. A., Tulaimat A., Herdegen J. J., Mokhlesi B. The effect of continuous positive airway pressure on glucose control in diabetic patients with severe obstructive sleep apnea. Sleep & Breathing = Schlaf & Atmung 2005; 9: 176–80. https://doi.org/10.1007/S11325-005-0033-Y.
Supplementary files
Review
For citations:
Ionin V.A., Pavlova V.A., Baranova E.I. Obstructive sleep apnea syndrome and cardiovascular diseases: from diagnosis to personalized therapy (part 1). Russian Journal for Personalized Medicine. 2022;2(2):46-53. (In Russ.) https://doi.org/10.18705/2782-3806-2022-2-2-46-53
Views:
521
Email this article 